Renal Cell Carcinoma – Pipeline Review, H2 2016

Global Markets Direct’s, ‘Renal Cell Carcinoma – Pipeline Review, H2 2016’, provides an overview of the Renal Cell Carcinoma pipeline landscape.

The report provides comprehensive information on the therapeutics under development for Renal Cell Carcinoma, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in therapeutic development for Renal Cell Carcinoma and features dormant and discontinued projects.

Global Markets Direct’s report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.

Note: Certain sections in the report may be removed or altered based on the availability and relevance of data.

Scope

The report provides a snapshot of the global therapeutic landscape of Renal Cell Carcinoma

The report reviews pipeline therapeutics for Renal Cell Carcinoma by companies and universities/research institutes based on information derived from company and industry-specific sources

The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages

The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities

The report reviews key players involved Renal Cell Carcinoma therapeutics and enlists all their major and minor projects

The report assesses Renal Cell Carcinoma therapeutics based on drug target, mechanism of action (MoA), route of administration (RoA) and molecule type

The report summarizes all the dormant and discontinued pipeline projects

The report reviews latest news related to pipeline therapeutics for Renal Cell Carcinoma

Reasons to buy

Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies

Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage

Identify and understand important and diverse types of therapeutics under development for Renal Cell Carcinoma

Identify potential new clients or partners in the target demographic

Develop strategic initiatives by understanding the focus areas of leading companies

Plan mergers and acquisitions effectively by identifying key players and it’s most promising pipeline therapeutics

Devise corrective measures for pipeline projects by understanding Renal Cell Carcinoma pipeline depth and focus of Indication therapeutics

Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope

Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline

Companies mentioned

AbbVie Inc

Acceleron Pharma, Inc.

Advenchen Laboratories, LLC

Altor BioScience Corporation

Ambrx, Inc.

Amgen Inc.

Ampio Pharmaceuticals, Inc.

Apac Biotech Pvt Ltd

arGEN-X BV

Argos Therapeutics, Inc.

ARMO Biosciences, Inc.

Arrowhead Pharmaceuticals, Inc.

Astellas Pharma Inc.

Bayer AG

Bio-Cancer Treatment International Limited

BIOCAD

Bionomics Limited

Bionovis SA

Boehringer Ingelheim GmbH

Boston Biomedical, Inc.

Bristol-Myers Squibb Company

Calithera Biosciences, Inc.

Cellceutix Corporation

Celldex Therapeutics, Inc.

Chipscreen Biosciences Ltd

Cytune Pharma SAS

Dr. Reddy's Laboratories Limited

EirGenix Inc.

Eisai Co., Ltd.

Eli Lilly and Company

Exelixis, Inc.

F. Hoffmann-La Roche Ltd.

Five Prime Therapeutics Inc

Gene Techno Science Co., Ltd.

Genor BioPharma Co Ltd

GlaxoSmithKline Plc

Hemispherx Biopharma, Inc.

Horizon Pharma Plc

Hutchison MediPharma Limited

Immatics Biotechnologies GmbH

Immune Design Corp.

Immunicum AB

ImmunoGen, Inc.

Immunomedics, Inc.

Incuron, LLC

Incyte Corporation

Inspyr Therapeutics Inc

Johnson & Johnson

KAHR medical Ltd.

Karyopharm Therapeutics, Inc.

KineMed, Inc.

Kyowa Hakko Kirin Co., Ltd.

Lead Discovery Center GmbH

Mabion SA

MacroGenics, Inc.

MedImmune LLC

Medivation, Inc.

Merck & Co., Inc.

Merck KGaA

Millennium Pharmaceuticals Inc

Molecular Partners AG

Mologen AG

Monopar Therapeutics LLC

Mycenax Biotech Inc.

Nektar Therapeutics

NewLink Genetics Corporation

Novartis AG

NovaTarg Therapeutics, Inc

Omeros Corporation

Oncobiologics, Inc.

OncoMax

Ono Pharmaceutical Co., Ltd.

Peloton Therapeutics, Inc.

Pfizer Inc.

Pharmacyclics Inc

Prima BioMed Ltd.

PsiOxus Therapeutics Limited

Rexahn Pharmaceuticals, Inc.

Richter Gedeon Nyrt.

Sevion Therapeutics, Inc.

Sillajen Biotherapeutics

Sorrento Therapeutics Inc

Sumitomo Dainippon Pharma Co Ltd

Syndax Pharmaceuticals Inc

Taiwan Liposome Company, Ltd.

Takeda Pharmaceutical Company Limited

Tara Immuno-Oncology Therapeutics LLC

TC BioPharm Limited

Theravectys SA

Tocagen Inc.

TRACON Pharmaceuticals Inc

TVAX Biomedical, Inc.

Tyrogenex, Inc.

Vascular Biogenics Ltd.

X4 Pharmaceuticals, Inc.

Table of Contents

Table of Contents

Table of Contents 2

Introduction 7

Renal Cell Carcinoma Overview 8

Therapeutics Development 9

Renal Cell Carcinoma - Therapeutics under Development by Companies 11

Renal Cell Carcinoma - Therapeutics under Investigation by Universities/Institutes 18

Renal Cell Carcinoma - Pipeline Products Glance 19

Renal Cell Carcinoma - Products under Development by Companies 23

Renal Cell Carcinoma - Products under Investigation by Universities/Institutes 34

Renal Cell Carcinoma - Companies Involved in Therapeutics Development 35

Renal Cell Carcinoma - Therapeutics Assessment 130

Drug Profiles 162

Renal Cell Carcinoma - Dormant Projects 738

Renal Cell Carcinoma - Discontinued Products 753

Renal Cell Carcinoma - Product Development Milestones 757

Appendix 775

List of Tables

List of Tables

Number of Products under Development for Renal Cell Carcinoma, H2 2016 26

Number of Products under Development for Renal Cell Carcinoma – Comparative Analysis, H2 2016 27

Number of Products under Development by Companies, H2 2016 28

Number of Products under Development by Companies, H2 2016 (Contd..1) 29

Number of Products under Development by Companies, H2 2016 (Contd..2) 30

Number of Products under Development by Companies, H2 2016 (Contd..3) 31

Number of Products under Development by Companies, H2 2016 (Contd..4) 32

Number of Products under Development by Companies, H2 2016 (Contd..5) 33

Number of Products under Development by Companies, H2 2016 (Contd..6) 34

Number of Products under Investigation by Universities/Institutes, H2 2016 35

Comparative Analysis by Late Stage Development, H2 2016 36

Comparative Analysis by Clinical Stage Development, H2 2016 37

Comparative Analysis by Early Stage Development, H2 2016 38

Comparative Analysis by Unknown Stage Development, H2 2016 39

Products under Development by Companies, H2 2016 40

Products under Development by Companies, H2 2016 (Contd..1) 41

Products under Development by Companies, H2 2016 (Contd..2) 42

Products under Development by Companies, H2 2016 (Contd..3) 43

Products under Development by Companies, H2 2016 (Contd..4) 44

Products under Development by Companies, H2 2016 (Contd..5) 45

Products under Development by Companies, H2 2016 (Contd..6) 46

Products under Development by Companies, H2 2016 (Contd..7) 47

Products under Development by Companies, H2 2016 (Contd..8) 48

Products under Development by Companies, H2 2016 (Contd..9) 49

Products under Development by Companies, H2 2016 (Contd..10) 50

Products under Investigation by Universities/Institutes, H2 2016 51

Renal Cell Carcinoma – Pipeline by AbbVie Inc, H2 2016 52

Renal Cell Carcinoma – Pipeline by Acceleron Pharma, Inc., H2 2016 53

Renal Cell Carcinoma – Pipeline by Advenchen Laboratories, LLC, H2 2016 54

Renal Cell Carcinoma – Pipeline by Altor BioScience Corporation, H2 2016 55

Renal Cell Carcinoma – Pipeline by Ambrx, Inc., H2 2016 56

Renal Cell Carcinoma – Pipeline by Amgen Inc., H2 2016 57

Renal Cell Carcinoma – Pipeline by Ampio Pharmaceuticals, Inc., H2 2016 58

Renal Cell Carcinoma – Pipeline by Apac Biotech Pvt Ltd, H2 2016 59

Renal Cell Carcinoma – Pipeline by arGEN-X BV, H2 2016 60

Renal Cell Carcinoma – Pipeline by Argos Therapeutics, Inc., H2 2016 61

Renal Cell Carcinoma – Pipeline by ARMO Biosciences, Inc., H2 2016 62

Renal Cell Carcinoma – Pipeline by Arrowhead Pharmaceuticals, Inc., H2 2016 63

Renal Cell Carcinoma – Pipeline by Astellas Pharma Inc., H2 2016 64

Renal Cell Carcinoma – Pipeline by Bayer AG, H2 2016 65

Renal Cell Carcinoma – Pipeline by Bio-Cancer Treatment International Limited, H2 2016 66

Renal Cell Carcinoma – Pipeline by BIOCAD, H2 2016 67

Renal Cell Carcinoma – Pipeline by Bionomics Limited, H2 2016 68

Renal Cell Carcinoma – Pipeline by Bionovis SA, H2 2016 69

Renal Cell Carcinoma – Pipeline by Boehringer Ingelheim GmbH, H2 2016 70

Renal Cell Carcinoma – Pipeline by Boston Biomedical, Inc., H2 2016 71

Renal Cell Carcinoma – Pipeline by Bristol-Myers Squibb Company, H2 2016 72

Renal Cell Carcinoma – Pipeline by Calithera Biosciences, Inc., H2 2016 73

Renal Cell Carcinoma – Pipeline by Cellceutix Corporation, H2 2016 74

Renal Cell Carcinoma – Pipeline by Celldex Therapeutics, Inc., H2 2016 75

Renal Cell Carcinoma – Pipeline by Chipscreen Biosciences Ltd, H2 2016 76

Renal Cell Carcinoma – Pipeline by Cytune Pharma SAS, H2 2016 77

Renal Cell Carcinoma – Pipeline by Dr. Reddy's Laboratories Limited, H2 2016 78

Renal Cell Carcinoma – Pipeline by EirGenix Inc., H2 2016 79

Renal Cell Carcinoma – Pipeline by Eisai Co., Ltd., H2 2016 80

Renal Cell Carcinoma – Pipeline by Eli Lilly and Company, H2 2016 81

Renal Cell Carcinoma – Pipeline by Exelixis, Inc., H2 2016 82

Renal Cell Carcinoma – Pipeline by F. Hoffmann-La Roche Ltd., H2 2016 83

Renal Cell Carcinoma – Pipeline by Five Prime Therapeutics Inc, H2 2016 84

Renal Cell Carcinoma – Pipeline by Gene Techno Science Co., Ltd., H2 2016 85

Renal Cell Carcinoma – Pipeline by Genor BioPharma Co Ltd, H2 2016 86

Renal Cell Carcinoma – Pipeline by GlaxoSmithKline Plc, H2 2016 87

Renal Cell Carcinoma – Pipeline by Hemispherx Biopharma, Inc., H2 2016 88

Renal Cell Carcinoma – Pipeline by Horizon Pharma Plc, H2 2016 89

Renal Cell Carcinoma – Pipeline by Hutchison MediPharma Limited, H2 2016 90

Renal Cell Carcinoma – Pipeline by Immatics Biotechnologies GmbH, H2 2016 91

Renal Cell Carcinoma – Pipeline by Immune Design Corp., H2 2016 92

Renal Cell Carcinoma – Pipeline by Immunicum AB, H2 2016 93

Renal Cell Carcinoma – Pipeline by ImmunoGen, Inc., H2 2016 94

Renal Cell Carcinoma – Pipeline by Immunomedics, Inc., H2 2016 95

Renal Cell Carcinoma – Pipeline by Incuron, LLC, H2 2016 96

Renal Cell Carcinoma – Pipeline by Incyte Corporation, H2 2016 97

Renal Cell Carcinoma – Pipeline by Inspyr Therapeutics Inc, H2 2016 98

Renal Cell Carcinoma – Pipeline by Johnson & Johnson, H2 2016 99

Renal Cell Carcinoma – Pipeline by KAHR medical Ltd., H2 2016 100

Renal Cell Carcinoma – Pipeline by Karyopharm Therapeutics, Inc., H2 2016 101

Renal Cell Carcinoma – Pipeline by KineMed, Inc., H2 2016 102

Renal Cell Carcinoma – Pipeline by Kyowa Hakko Kirin Co., Ltd., H2 2016 103

Renal Cell Carcinoma – Pipeline by Lead Discovery Center GmbH, H2 2016 104

Renal Cell Carcinoma – Pipeline by Mabion SA, H2 2016 105

Renal Cell Carcinoma – Pipeline by MacroGenics, Inc., H2 2016 106

Renal Cell Carcinoma – Pipeline by MedImmune LLC, H2 2016 107

Renal Cell Carcinoma – Pipeline by Medivation, Inc., H2 2016 108

Renal Cell Carcinoma – Pipeline by Merck & Co., Inc., H2 2016 109

Renal Cell Carcinoma – Pipeline by Merck KGaA, H2 2016 110

Renal Cell Carcinoma – Pipeline by Millennium Pharmaceuticals Inc, H2 2016 111

Renal Cell Carcinoma – Pipeline by Molecular Partners AG, H2 2016 112

Renal Cell Carcinoma – Pipeline by Mologen AG, H2 2016 113

Renal Cell Carcinoma – Pipeline by Monopar Therapeutics LLC, H2 2016 114

Renal Cell Carcinoma – Pipeline by Mycenax Biotech Inc., H2 2016 115

Renal Cell Carcinoma – Pipeline by Nektar Therapeutics, H2 2016 116

Renal Cell Carcinoma – Pipeline by NewLink Genetics Corporation, H2 2016 117

Renal Cell Carcinoma – Pipeline by Novartis AG, H2 2016 118

Renal Cell Carcinoma – Pipeline by NovaTarg Therapeutics, Inc, H2 2016 119

Renal Cell Carcinoma – Pipeline by Omeros Corporation, H2 2016 120

Renal Cell Carcinoma – Pipeline by Oncobiologics, Inc., H2 2016 121

Renal Cell Carcinoma – Pipeline by OncoMax, H2 2016 122

Renal Cell Carcinoma – Pipeline by Ono Pharmaceutical Co., Ltd., H2 2016 123

Renal Cell Carcinoma – Pipeline by Peloton Therapeutics, Inc., H2 2016 124

Renal Cell Carcinoma – Pipeline by Pfizer Inc., H2 2016 125

Renal Cell Carcinoma – Pipeline by Pharmacyclics Inc, H2 2016 126

Renal Cell Carcinoma – Pipeline by Prima BioMed Ltd., H2 2016 127

Renal Cell Carcinoma – Pipeline by PsiOxus Therapeutics Limited, H2 2016 128

Renal Cell Carcinoma – Pipeline by Rexahn Pharmaceuticals, Inc., H2 2016 129

Renal Cell Carcinoma – Pipeline by Richter Gedeon Nyrt., H2 2016 130

Renal Cell Carcinoma – Pipeline by Sevion Therapeutics, Inc., H2 2016 131

Renal Cell Carcinoma – Pipeline by Sillajen Biotherapeutics, H2 2016 132

Renal Cell Carcinoma – Pipeline by Sorrento Therapeutics Inc, H2 2016 133

Renal Cell Carcinoma – Pipeline by Sumitomo Dainippon Pharma Co Ltd, H2 2016 134

Renal Cell Carcinoma – Pipeline by Syndax Pharmaceuticals Inc, H2 2016 135

Renal Cell Carcinoma – Pipeline by Taiwan Liposome Company, Ltd., H2 2016 136

Renal Cell Carcinoma – Pipeline by Takeda Pharmaceutical Company Limited, H2 2016 137

Renal Cell Carcinoma – Pipeline by Tara Immuno-Oncology Therapeutics LLC, H2 2016 138

Renal Cell Carcinoma – Pipeline by TC BioPharm Limited, H2 2016 139

Renal Cell Carcinoma – Pipeline by Theravectys SA, H2 2016 140

Renal Cell Carcinoma – Pipeline by Tocagen Inc., H2 2016 141

Renal Cell Carcinoma – Pipeline by TRACON Pharmaceuticals Inc, H2 2016 142

Renal Cell Carcinoma – Pipeline by TVAX Biomedical, Inc., H2 2016 143

Renal Cell Carcinoma – Pipeline by Tyrogenex, Inc., H2 2016 144

Renal Cell Carcinoma – Pipeline by Vascular Biogenics Ltd., H2 2016 145

Renal Cell Carcinoma – Pipeline by X4 Pharmaceuticals, Inc., H2 2016 146

Assessment by Monotherapy Products, H2 2016 147

Assessment by Combination Products, H2 2016 148

Number of Products by Stage and Target, H2 2016 150

Number of Products by Stage and Mechanism of Action, H2 2016 163

Number of Products by Stage and Route of Administration, H2 2016 176

Number of Products by Stage and Molecule Type, H2 2016 178

Renal Cell Carcinoma – Dormant Projects, H2 2016 754

Renal Cell Carcinoma – Dormant Projects (Contd..1), H2 2016 755

Renal Cell Carcinoma – Dormant Projects (Contd..2), H2 2016 756

Renal Cell Carcinoma – Dormant Projects (Contd..3), H2 2016 757

Renal Cell Carcinoma – Dormant Projects (Contd..4), H2 2016 758

Renal Cell Carcinoma – Dormant Projects (Contd..5), H2 2016 759

Renal Cell Carcinoma – Dormant Projects (Contd..6), H2 2016 760

Renal Cell Carcinoma – Dormant Projects (Contd..7), H2 2016 761

Renal Cell Carcinoma – Dormant Projects (Contd..8), H2 2016 762

Renal Cell Carcinoma – Dormant Projects (Contd..9), H2 2016 763

Renal Cell Carcinoma – Dormant Projects (Contd..10), H2 2016 764

Renal Cell Carcinoma – Dormant Projects (Contd..11), H2 2016 765

Renal Cell Carcinoma – Dormant Projects (Contd..12), H2 2016 766

Renal Cell Carcinoma – Dormant Projects (Contd..13), H2 2016 767

Renal Cell Carcinoma – Dormant Projects (Contd..14), H2 2016 768

Renal Cell Carcinoma – Discontinued Products, H2 2016 769

Renal Cell Carcinoma – Discontinued Products (Contd..1), H2 2016 770

Renal Cell Carcinoma – Discontinued Products (Contd..2), H2 2016 771

Renal Cell Carcinoma – Discontinued Products (Contd..3), H2 2016 772

List of Figures

List of Figures

Number of Products under Development for Renal Cell Carcinoma, H2 2016 26

Number of Products under Development for Renal Cell Carcinoma – Comparative Analysis, H2 2016 27

Number of Products under Development by Companies, H2 2016 28

Number of Products under Investigation by Universities/Institutes, H2 2016 35

Comparative Analysis by Late Stage Development, H2 2016 36

Comparative Analysis by Clinical Stage Development, H2 2016 37

Comparative Analysis by Early Stage Products, H2 2016 38

Assessment by Monotherapy Products, H2 2016 147

Assessment by Combination Products, H2 2016 148

Number of Products by Top 10 Targets, H2 2016 149

Number of Products by Stage and Top 10 Targets, H2 2016 149

Number of Products by Top 10 Mechanism of Actions, H2 2016 162

Number of Products by Stage and Top 10 Mechanism of Actions, H2 2016 162

Number of Products by Top 10 Routes of Administration, H2 2016 175

Number of Products by Stage and Top 10 Routes of Administration, H2 2016 175

Number of Products by Top 10 Molecule Types, H2 2016 177

Number of Products by Stage and Top 10 Molecule Types, H2 2016 177

    Pricing

Discounts available for multiple report purchases.

reportstore@globalmarketsdirect.com
+44 (0) 161 359 5414

Saved reports